^
Association details:
| Biomarker: | TCF3-EPAS1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | alisertib (MLN8237) (Aurora kinase A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia
Published date:
11/01/2018
Excerpt:
Each sample was tested in vivo in cohorts of vehicle (n=5) and alisertib (30mg/kg/day; n=5). All five ALL samples showed significant response (p<0.01 for all five samples compared to their respective vehicle controls by Chi Square analysis)....Our results suggest that TCF3-HLF ALL is a heterogeneous subset of ALL with both different gene expression patterns from TCF3-HLF to other fusions as well as functional drug response.
DOI:
https://doi.org/10.1182/blood-2018-99-115706
